Table 5.
Treatments 1 | Disease Severity 2 (%) | Reduction of Disease Severity (%) |
---|---|---|
Control | 39.7 e | |
SA 100 ppm | 27.4 a–c | 30.9 |
CS 100 ppm | 32.0 cd | 19.3 |
SN 100 ppm | 30.3 b–d | 23.8 |
Pyr | 33.9 d | 14.7 |
Flu | 25.6 ab | 35.4 |
ZON | 34.1 d | 14.2 |
N6-200 | 24.8 a | 37.4 |
N6-400 | 25.0 a | 37.0 |
N6-800 | 24.7 a | 37.7 |
N3-400 | 25.0 a | 37.0 |
F-test | ** | |
CV (%) | 10.87 |
1 SA-Salicylic acid 100 ppm; CS-Chitosan 100 ppm; SN-Silver nitrate 100 ppm; Pyr-Pyraclostrobin, Headline® 10 mL/20 L; Flu-Flutriafol, JOINT® 30 mL/20 L; ZON-Zinc oxide NP, ZONO-S1® 20 mL/20 L. The CS (0.4% or 0.5%) and Pentasodium triphosphate (0.2% or 0.5%) were mixed with SA 0.2% or silver nitrate 3 mM to prepare a formulation of CS-NP-loaded SA (N3) or a formulation of CS-NP-loaded Ag (N6), respectively. 2 Means followed by the same letter do not differ significantly according to DMRT at p ≤ 0.01 (**).